arrow
B

Benjamin L. Schlechter

Dana-Farber Cancer Institute and Harvard Medical School
H指数:19
被引数:1,218

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial

奥拉帕尼与尼沃鲁单抗联合治疗微卫星稳定型结直肠癌:一项1/2期临床试验

2026-07-230
OA
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial

吉西他滨和nab-紫杉醇联合或不联合VDR激动剂帕立骨化醇治疗转移性胰腺癌: 一项随机,多臂,磨合期试验

2026-05-250
PRE
Autologous T Cell Antigen Coupler Targeting HER2 (TAC01-HER2) in Advanced or Metastatic Solid Tumors

自体T细胞抗原偶联物靶向HER2(TAC01-HER2)在晚期或转移性实体瘤中的应用

2026-05-220
PRE
Phase 2 Trial Testing The PARP Inhibitor Niraparib In Patients With Advanced Pancreatic Cancer with Pathogenic Variants In BRCA 1, BRCA2, PALB2, ATM and CHEK2
2024-09-150
PRE
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
2024-06-1310
OAAI
A phase 1 expansion cohort study evaluating the safety and efficacy of the CHK1 inhibitor LY2880070 with low-dose gemcitabine in metastatic pancreatic adenocarcinoma
2024-01-160
PRE
NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)
2023-12-010
PRE
Phase II study of NUC-3373, leucovorin, irinotecan (NUFIRI) plus bevacizumab vs FOLFIRI plus bevacizumab for the second-line treatment of patients with advanced/metastatic colorectal cancer (NuTide:323)
2023-12-010
PRE
Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
2023-06-0110
OA